Summary
The renal haemodynamics of a particular patient may affect the pharmacological and pharmacokinetic properties of various drugs. For example, diminution in renal haemodynamics may lead to fluid retention and an increase in the volume of distribution of the drug. Also, fluid retention causes a decrease in plasma protein concentration which for certain drugs can result in altered protein binding and consequently increased proportion of unbound drug and a more marked pharmacological response.
The clearance of many drugs and/or metabolites also in influenced by the stale of renal haemodynamics. In states of poor renal perfusion, drugs which are mainly eliminated through renal mechanisms have a reduced rate of clearance. The resultant prolongation of the elimination half-life of the drug may increase its toxicity. Knowledge of the renal haemodynamic state, therefore, should be considered in determining the dose and frequency of drug administration.
Studies in man have shown that both renal blood flow and glomerular filtration rate are reduced below normal in states of congestive heart failure, liver disorders such as cirrhosis, and, of course, acute and chronic renal failure. In these pathological states, severe cortical vasoconstriction may be present and primarily account for the impairment in renal haemodynamics and alterations in drug kinetics and action.
Not only can the renal haemodynamic state affect the actions of drugs, but also exogenous administration of certain drugs can alter renal haemodynamics. The kidney’s response to these agents is influenced by pathological and physiological factors, including sodium balance and the ability of the kidney to autoregulate its blood flow. In general, however, renal haemodynamics are diminished by renal vasoconstrictors and improved by renal vasodilators. The altered state of renal haemodynamics in turn may modify the pharmacological and pharmacokinetic properties of other drugs present in the body.
Similar content being viewed by others
References
Abrams, H.L.; Boijsen, E. and Borgstromke, K.E.: Effect of epinephrine on the renal circulation. Radiology 79: 911–922 (1962).
Ahlquist, P.P.; Taylor, J.P.: Rawson, C.W. and Sydour, V.L.: Comparative effects of epinephrine and levarterenol in the intact anesthetized dog. Journal of Pharmacology and Experimental Therapeutics 110: 352–360 (1964).
Baer, P.G. and Navar, L.G.: Renal vasodilation and uncoupling of blood flow and filtration rate autoregulation. Kidney International 5: 12–21 (1973).
Bennett, W.M. and Craven, R.: Urinary tract infections in patients with severe renal disease. Treatment with ampicillin and trimethoprim-sulfamethoxazole. Journal of the American Medical Association 236: 946–948 (1976).
Bianchetti, G.; Graziani, G.; Brancaccio, D.; Morganti, A.; Leonetti, G.; Manfrin, M.; Sega, R.; Gomeni, R.; Ponticelli, C. and Morselli, P.L.: Pharmacokinetics and effects of propranolol in terminal uraemic patients and in patients undergoing regular dialysis treatment. Clinical Pharmacokinetics 1: 373–384 (1976).
Boston Collaborative Drug Surveillance Program: Diphenylhydantoin side effects and serum albumin levels. Clinical Pharmacology and Therapeutics 14: 529–532 (1973).
Brenner, B.M.; Baylis, C. and Deen, W.M.: Transport of molecules across renal glomerular capillaries. Physiological Reviews 56: 502–534 (1976).
Cafruny, E.J.: Renal tubular handling of drugs. American Journal of Medicine 62: 490–496 (1977).
Craig, W.A. and Kunin, C.M.: Trimethoprim-sulfamethoxazole. Pharmacodynamic effects of urinary pH and impaired renal function. Annals of Internal Medicine 78: 491–497 (1973).
Davis. J.M. and Fann, W.E.: Lithium. Annual Review of Pharmacology 11: 285–302 (1971).
Dorer, F.; Kahn, JR.; Lentz, K.E.; Levine, M. and Skeggs, L.T.: Hydrolysis of bradykinin by angiotensin converting enzyme. Circulation Research 34: 824–827 (1974).
Duchin, K.L.; Peterson, L.N. and Burke. T.J.: Effect of furosemide on renal autoregulation, Kidney International (In press).
Epstein, M.; Hollenberg, N.K. and Merrill, J.P.: The pattern of the renal vascular response to epinephrine in man. Proceedings of the Society for Biology and Experimental Medicine 134: 720–724 (1970).
Epstein, M.; Schneider, N. and Befeler, B.: Relationship of systemic and intrarenal haemodynamics in cirrhosis. Journal of Laboratory and Clinical Medicine 89: 1175–1187 (1977).
Fabre, J. and Balant, L.: Renal failure, drug pharmacokinetics and drug action. Clinical Pharmacokinetics 1: 99–120 (1976).
Falch. D.: The influence of kidney function, body size and age on plasma concentration and urinary excretion of digoxin. Acta Medica Scandinavica 194: 251–256 (1973).
Ghoneim, M.M.; Kramer, E.; Bannow, R.; Pandya, H. and Routh, J.I.: Binding of d-tubocurarine to plasma proteins in normal man and in patients with hepatic or renal disease. Anesthesiology 39: 410–415 (1973).
Goldberg, L.I.; McDonald, R.H. Jr. and Zimmerman. A.M.: Sodium diuresis in patients with congestive heart failure. New England Journal of Medicine 269: 1060–1064 (1963).
Gugler. R. and Azarnoff. D.L.: Drug protein binding and the nephrotic syndrome. Clinical Pharmacokinetics 1: 25–35 (1976).
Gugler, R.; Shoeman, D.W.; Huffman. D.H.; Cohlmia. J.B. and Azarnoff, D.L.: Pharmacokinetics of drugs in patients with the nephrotic syndrome. Journal of Clinical Investigation 55: 1182–1189 (1975).
Hollenberg, N.K.; Adams, D.F.; Solomon. H.; Chenitz, W.R.; Burger, B.M.; Abrams, H.L. and Merrill. J.P.: Renal vascular tone in essential and secondary hypertension. Medicine (Baltimore) 54: 29–44 (1975).
Hollenberg, N.K.; Adams, D.F.: Solomon, H.S.; Rashid, A.; Abrams, H.L. and Merrill, J.P.: Senescence and the renal vasculature in normal man. Circulation Research 34: 309–316 (1974).
Hollenberg. N.K.: Epstein. M.: Rosen. S.M.; Basch. R.I.; Oken. D.E. and Merrill, J.P.: Acute oliguric renal failure in man: Evidence for preferential renal cortical ischemia. Medicine 47: 455–474 (1968).
Hook, J.B.; Blatt. A.H.; Brody, M.F. and Williamson. H.E.: Effects of several saluretic-diuretic agents on renal hemodynamics. Journal of Pharmacology and Experimental Therapeutics 154: 667–673 (1966).
Inaska, T.: Studies of the intrarenal distribution of blood flow with xenon 133 in diseased human kidney. Japanese Circulation Journal 33: 737–748 (1969).
Kew, M.C.; Brunt, P.W.; Varma, R.R.; Hourigan, K.J.; Williams, H.S. and Sherlock, S.: Renal and intrarenal blood flow in cirrhosis of the liver. Lancet 4: 405–510 (1971).
Kilcoyne, M.M.; Schmidt, D.H. and Cannon, P.J.: Intrarenal blood flow in congestive heart failure. Circulation 47: 786–797 (1973).
Kleinknecht. D.; Grunfeld, J.P.; Gomez, P.C.; Moreau, J.F. and Garcia-Torris, R.: Diagnostic procedures and long-term prognosis in bilateral renal cortical necrosis. Kidney International 4: 390–400 (1973).
Knox, F.G.; Cuche, J.; Ott, C.E.; Diaz-Buxo, J.A. and Marchand, G.: Regulation of glomerular filtration and proximal tubule reabsorption. Circulation Research 36: I–107–I–118 (1975).
Kones, R.J. and Phillips, J.H.: Glucagon: present status in cardiovascular disease. Clinical Pharmacology and Therapeutics 12: 427–444 (1971).
Letteri, J.M.; Mellk, H.; Louis, S.; Kutt, H.; Durante, P. and Glazko, A.: Diphenylhydantoin metabolism in uremia. New England Journal of Medicine 285: 648–652 (1971).
Lewis, G.P.; Jusko, W.J.; Burke, C.W.; Graves. L.: Prednisone side-effects and serum protein levels. Lancet 2: 778–780 (1971).
MacCannell. K.L.; McNay, J.L.; Meyer, M.B. and Goldberg, L.I.: Dopamine in the treatment of hypotension and shock. New England Journal of Medicine 275: 1389–1398 (1966).
McDonald, R.H. Jr.; Goldberg, L.I. and McNay, J.L.: Effects of dopamine in man: augmentation of sodium excretion, glomerular filtration rate, and renal plasma flow. Journal of Clinical Investigation 43: 1116–1124 (1964).
McNay, J.L. and Goldberg, L.I.: Comparison of the effects of dopamine, isoproterenol, norepinephrine and bradykinin on canine renal and femoral blood flow. Journal of Pharmacology and Experimental Therapeutics 151: 23–31 (1966).
Millard, R.W.; Higgins, C.B.; Franklin, D. and Vatner, S.F.: Regulation of the renal circulation during severe exercise in normal dogs and dogs with experimental heart failure. Circulation Research 31: 881–888 (1972).
Mimram, A.; Guiod, L. and Hollenberg, N.K.: The role of angiotensin in the cardiovascular and renal response to salt restriction. Kidney International 5: 348–355 (1974).
Odar-Cederlof. I.: Plasma protein binding of Phenytoin and warfarin in patients undergoing renal transplantation. Clinical Pharmacokinetics 2: 147–153 (1977).
Odar-Cederlof. I. and Borga, O.: Kinetics of diphenylhydantoin in uraemic patients: consequences of decreased plasma protein binding. European Journal of Clinical Pharmacology 7: 31–37 (1974).
Olsen, G.D.; Bennett, W.M. and Porter, G.A.: Morphine and Phenytoin binding to plasma proteins in renal and hepatic failure. Clinical Pharmacology and Therapeutics 17: 677–684 (1975).
Pals, D.T.; Masucci. F.D.; Denning. Jr.; G.S.; Sipos, F. and Fessier, D.C.: Role of the pressor action of angiotensin II in experimental hypertension. Circulation Research 29: 673–681 (1971).
Pearson, R.M.: Pharmacokinetics and response to diazoxide in renal failure. Clinical Pharmacokinetics 2: 198–204 (1977).
Pearson. R.M. and Breckenridge, A.M.: Renal function, protein binding and pharmacologic response to diazoxide. British Journal of Clinical Pharmacology 3: 169–175 (1976).
Pitts. R.F.: Physiology of the Kidney and Body Fluids, pp 144–161 (Year Book, Chicago 1963).
Reidenberg, M.M.: The binding of drugs to plasma proteins from patients with poor renal function. Clinical Pharmacokinetics 1: 121–125 (1976).
Reidenberg, M.M.: The binding of drugs to plasma proteins and the interpretation of measurements of plasma concetrations of drugs in patients with poor renal function. American Journal of Medicine 62: 466–470 (1977).
Reidenberg, M.M.: Renal Function and Drug Action, pp. 5–17 (Saunders, Philadelphia 1971).
Reidenberg, M.M. and Affrime, M.: Influence of disease on binding of drugs to plasma proteins. Annals of the New York Academy of Sciences 226: 115–126 (1973).
Schroeder, E.T.; Shear, L.; Sanietta, S.M. and Gobuzda, G.J.: Renal failure in patients with cirrhosis of the liver. American Journal of Medicine 43: 887–896 (1967).
Selkurt, E.E.; Hall, P.W. and Spencer, M.P.: Influence of graded arterial pressure decrement on renal clearance of creatinine, p-amino hippurate and sodium. American Journal of Physiology 159: 369–378 (1949).
Sjoholm, I.; Kober, A.; Odar-Cederlof, I. and Borga, O.: Protein binding of drugs in uraemic and normal serum. The role of endogenous binding inhibitors. Biochemical Pharmacology 25: 1205–1213 (1976).
Strewler, G.J.; Hinrichs, K.J.; Guiod. L.R. and Hollenberg, N.K.: Sodium intake and vascular smooth muscle responsiveness to norepinephrine and angiotensin in the rabbit. Circulation Research 31: 758–766 (1972).
Varma. D.R.; Gupta, R.K.; Gupta, S. and Sharma, K.K.: Prothrombin response to phenindione during hypoalbuminaemia. British Journal of Clinical Pharmacology 2: 467–468 (1975).
Velasquez, M.T.; Notargiacomo, A.V. and Cohn, J.N.: Comparative effects of saline and mannitol on renal cortical blood flow and volume in the dog. American Journal of Physiology 224: 322–327 (1973).
Weiner, I.M.: Mechanisms of drug absorption and excretion. Annual Review of Pharmacology 7: 39–56 (1967).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Duchin, K.L., Schrier, R.W. Interrelationship Between Renal Haemodynamics, Drug Kinetics and Drug Action. Clin Pharmacokinet 3, 58–71 (1978). https://doi.org/10.2165/00003088-197803010-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-197803010-00004